Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
Spasticity is a disabling symptom of MS that is enhanced during interferon beta-lb (IFNbeta-1b) treatment. Nineteen patients with primary progressive MS were treated with IFNbeta-1b; an additional 19 patients did not receive this treatment. Thirteen of the 19 patients treated with IFNbeta-1b had increased spasticity requiring increased antispasticity drug administration. This observation suggests that further studies are needed before interferons can be so widely used in primary progressive MS patients.
Bramanti
P
P
Centro per lo Studio ed il Trattamento dei Neurolesi Lungodegenti, Cattedra di Neurofisiopatologia, University of Messina, Italy.
Sessa
E
E
Rifici
C
C
D'Aleo
G
G
Floridia
D
D
Di Bella
P
P
Lublin
F
F
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D018450:Disease Progression; D006801:Humans; D007167:Immunotherapy; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000150:complications / Q000628:therapy*; D009128:Muscle Spasticity / Q000139:chemically induced* / Q000209:etiology
D000276:Adjuvants, Immunologic; D016899:Interferon-beta